Navigation Links
Tight Blood Pressure Control Doesn't Help All Diabetics: Study
Date:7/6/2010

By Amanda Gardner
HealthDay Reporter

TUESDAY, July 6 (HealthDay News) -- Lower may not be better when it concerns blood pressure levels in type 2 diabetics who also have heart disease.

New research finds that patients with diabetes and coronary artery disease did not have fewer strokes or heart attacks, and actually were more likely to die when their blood pressure was maintained under 130 mm Hg, compared to patients with "usual blood pressure control," putting them in the 130 to 140 range.

In healthy adults, blood pressure levels of 120/80 are recommended.

"We found that after a mean follow-up of just under three years in patients with diabetes and coronary artery disease, lowering systolic blood pressure [the top number] to less than 130 . . . did not have any benefit compared to lowering blood pressure to between 130 and 140," said Rhonda Cooper-DeHoff, lead author of the study published in the July 7 issue of the Journal of the American Medical Association.

These findings, along with similar data recently released from the large ACCORD study, would suggest that "lowering blood pressure intensively does not provide any benefit over and above usual blood pressure reduction," said Cooper-DeHoff, who is associate professor of pharmacotherapy and translational research and division of cardiovascular medicine at the Colleges of Pharmacy and Medicine, University of Florida, Gainesville.

Time would be better spent focusing on other modifiable heart disease risk factors, such as cholesterol, she advised.

Various organizations, including the American Diabetes Association, currently recommend that diabetics keep their blood pressure under 130/80 mm Hg, but it's been less clear what to recommend for patients with type 2 diabetes and coronary artery disease.

To this end, the researchers involved in the new study analyzed data on 6,400 type 2 diabetics aged 50 or over who also had coronary artery disease. The participants were part of a larger trial investigating whether specific medication regimens were better than others for preventing heart attacks and other long-term heart problems.

Volunteers first received either a calcium antagonist or beta blocker, then an ACE inhibitor or a diuretic or both. The goal was to reach blood pressure levels of 130/85.

Individuals in the study who had blood pressure between 130 mm Hg and 140 mm Hg (usual control) and those who maintained tight control (less than 130 mm Hg) had roughly the same rate of cardiovascular events.

And, for the first time, the results showed that individuals with systolic blood pressure under 120 had a 15 percent higher risk of dying than those with the higher blood pressure readings.

"We don't need to push below 130 so maybe we save a blood pressure medication and save some of those adverse effects associated with extra [blood pressure] medication and concentrate on some other goals that are still important in patients with diabetes," said Cooper-DeHoff.

The trial was partially funded by Abbott Laboratories.

More information

The American Diabetes Association has more on living with type 2 diabetes and high blood pressure.

SOURCES: Rhonda Cooper-DeHoff, Pharm.D., associate professor, department of pharmacotherapy and translational research and division of cardiovascular medicine, Colleges of Pharmacy and Medicine, University of Florida, Gainesville; July 7, 2010, Journal of the American Medical Association


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Tight Blood Sugar Control in Older Diabetics May Not Reduce Heart Risk
2. Tight Blood Sugar Control May Not Harm Diabetics
3. FDA Tightens Oversight of Home Medical Devices
4. IBM Enterprise CloneDR Helps Enterprises Transform Bloated COBOL into Clean, Tight, and Maintainable Code
5. FDA Tightens Controls on Anemia Drugs
6. Tight Blood Sugar Control May Raise Risk of Death
7. Tighter Blood Sugar Control Not Best for Some Diabetics
8. Researchers identify factors behind blood-making stem cells
9. Diagnostic blood test can identify rare lung disease
10. Insulin Pump With Blood Sugar Sensor May Improve on Injections
11. Sensor and insulin pump results in better blood-sugar control in all age groups with diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
Breaking Medicine Technology: